The abstract is read at the publisher; the summary is JClub's.
RO7589831 (VVD-133214), a WRN covalent inhibitor, showed manageable safety in 88 patients with MSI and/or deficient DNA mismatch repair advanced solid tumors, with DCR 74.2% (49/66).
- Why it matters: WRN is a synthetic lethal target in MSI cancers, but first-in-human dosing, tolerability, and evidence of biological activity are needed to justify further development.
- What they did: In part 1 of an ongoing phase 1 trial, escalating RO7589831 doses were given once daily (150 mg), twice daily (150–1,000 mg), or three-times daily (200–600 mg), with safety and RP2D selection as primary goals.
- The result: No grade 5 TEAEs occurred, and exploratory ctDNA and FDG-PET responses supported biological activity; 150-mg and 600-mg BID were selected as RP2Ds for optimization.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.